Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]
- Market Cap ₹ 1,993 Cr.
- Current Price ₹ 852
- High / Low ₹ 1,651 / 788
- Stock P/E 150
- Book Value ₹ 308
- Dividend Yield 0.23 %
- ROCE 6.93 %
- ROE 4.78 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 2.76 times its book value
- Company has a low return on equity of 11.9% over last 3 years.
- Dividend payout has been low at 10.5% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -7.15%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of BSE Commodities BSE SmallCap BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
131 | 203 | 254 | 291 | 428 | 403 | 379 | 355 | |
110 | 170 | 201 | 226 | 322 | 348 | 312 | 316 | |
Operating Profit | 22 | 33 | 53 | 65 | 106 | 55 | 67 | 39 |
OPM % | 16% | 16% | 21% | 22% | 25% | 14% | 18% | 11% |
2 | 1 | 1 | 5 | 11 | 2 | 7 | 8 | |
Interest | 3 | 4 | 4 | 4 | 5 | 9 | 7 | 1 |
Depreciation | 3 | 4 | 5 | 7 | 8 | 10 | 26 | 26 |
Profit before tax | 18 | 26 | 44 | 59 | 103 | 39 | 42 | 19 |
Tax % | 38% | 24% | 21% | 13% | 7% | -4% | 31% | |
11 | 20 | 35 | 51 | 96 | 40 | 29 | 13 | |
EPS in Rs | 13.74 | 25.13 | 43.51 | 25.57 | 43.31 | 18.26 | 12.55 | 5.70 |
Dividend Payout % | 0% | 0% | 0% | 20% | 5% | 11% | 16% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 13% |
3 Years: | 9% |
TTM: | -18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | -17% |
TTM: | -72% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -30% |
1 Year: | -46% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 12% |
Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 20 | 22 | 22 | 23 | 23 |
Reserves | 51 | 72 | 106 | 142 | 447 | 483 | 702 | 698 |
56 | 77 | 91 | 90 | 120 | 170 | 14 | 15 | |
29 | 31 | 40 | 58 | 87 | 80 | 75 | 65 | |
Total Liabilities | 145 | 187 | 245 | 310 | 676 | 755 | 815 | 801 |
57 | 67 | 111 | 120 | 160 | 196 | 427 | 425 | |
CWIP | 10 | 6 | 5 | 10 | 51 | 231 | 77 | 114 |
Investments | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 1 |
76 | 114 | 129 | 179 | 464 | 327 | 301 | 262 | |
Total Assets | 145 | 187 | 245 | 310 | 676 | 755 | 815 | 801 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
25 | 19 | 20 | 24 | 103 | |||
-40 | -21 | -197 | -101 | -121 | |||
10 | -5 | 235 | 38 | 31 | |||
Net Cash Flow | -6 | -6 | 58 | -40 | 13 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 92 | 80 | 73 | 113 | 53 | 82 | 66 |
Inventory Days | 134 | 98 | 165 | 168 | 299 | 249 | 313 |
Days Payable | 132 | 70 | 88 | 116 | 82 | 52 | 96 |
Cash Conversion Cycle | 94 | 109 | 150 | 166 | 269 | 278 | 282 |
Working Capital Days | 105 | 117 | 103 | 152 | 164 | 172 | 167 |
ROCE % | 22% | 27% | 28% | 26% | 8% | 7% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
4 Dec - Schedule of investor meeting on December 10, 2024.
-
Announcement under Regulation 30 (LODR)-Credit Rating
6 Nov - CRISIL revises credit rating outlook to negative.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 Oct - Transcript of the earnings call held on 25 October 2024 post announcement of financial results of the Company for the quarter and half year ended …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
26 Oct - Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Half year ended 30 September 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
25 Oct - Earnings call recording available on company website.
Annual reports
Concalls
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT REC
-
May 2024Transcript PPT REC
-
Jan 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Jul 2022Transcript PPT
-
Apr 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021TranscriptPPT
-
Sep 2021TranscriptPPT
Leading Chemical Manufacturer[1]
It is the largest manufacturer of Structure Directing Agents (SDA) for Zeolites in India.